The influence of alpha 1-adrenergic blockade on the acute antihypertensive effect of nifedipine
- PMID: 2866964
- DOI: 10.1007/BF00544078
The influence of alpha 1-adrenergic blockade on the acute antihypertensive effect of nifedipine
Abstract
The hypotensive effect of vasodilator monotherapy in hypertension is attenuated by a baroreceptor-mediated increase in the sympathetic release of noradrenaline. Nifedipine induces a rise in noradrenaline release, but it is not known to affect noradrenaline-induced vascular contraction of smooth muscle to a clinically significant degree. The haemodynamic and hormonal effects of a single sublingual dose of nifedipine 20 mg in 8 moderately hypertensive patients have been studied before and during postsynaptic alpha 1-blockade with prazosin. The antihypertensive effect of nifedipine was significantly increased by prazosin pretreatment (fall in mean arterial pressure 60 min after nifedipine: -16.7% with and -8.5% without prazosin), despite similar increases in plasma noradrenaline. Prazosin alone caused no change in supine blood pressure for 2 h after an oral dose of 2 mg. The findings are in keeping with the hypothesis that prazosin blocks a compensatory reaction to vasodilatation caused by nifedipine.
Similar articles
-
Alpha-adrenergic blockade makes minimal contribution to ketanserin's hypotensive effect.Clin Pharmacol Ther. 1988 Dec;44(6):699-703. doi: 10.1038/clpt.1988.214. Clin Pharmacol Ther. 1988. PMID: 2904312 Clinical Trial.
-
The hypotensive effect of trimazosin is not caused solely by alpha 1-adrenoceptor blockade.J Cardiovasc Pharmacol. 1984 Jan-Feb;6(1):142-50. J Cardiovasc Pharmacol. 1984. PMID: 6199597
-
Cardiovascular profile and hypotensive mechanism of ketanserin in the rabbit.Hypertension. 1985 Jul-Aug;7(4):499-506. doi: 10.1161/01.hyp.7.4.499. Hypertension. 1985. PMID: 2861161
-
Alpha 1-blocking properties of carvedilol during acute and chronic administration.J Cardiovasc Pharmacol. 1992;19 Suppl 1:S18-22. doi: 10.1097/00005344-199219001-00005. J Cardiovasc Pharmacol. 1992. PMID: 1378144 Clinical Trial.
-
Nifedipine interactions in hypertensive patients.Cardiovasc Drugs Ther. 1990 Aug;4 Suppl 5:963-8. doi: 10.1007/BF02018301. Cardiovasc Drugs Ther. 1990. PMID: 2076408 Review.
Cited by
-
The mechanism of action of calcium antagonists on arrhythmias in early myocardial ischaemia: studies with nifedipine and DHM9.Br J Pharmacol. 1988 Aug;94(4):1275-86. doi: 10.1111/j.1476-5381.1988.tb11648.x. Br J Pharmacol. 1988. PMID: 3207985 Free PMC article.
-
Calcium channel antagonists. Part IV: Side effects and contraindications drug interactions and combinations.Cardiovasc Drugs Ther. 1988 Jul;2(2):177-89. doi: 10.1007/BF00051233. Cardiovasc Drugs Ther. 1988. PMID: 3154704 Review.
-
Calcium channel antagonists. Part III: Use and comparative efficacy in hypertension and supraventricular arrhythmias. Minor indications.Cardiovasc Drugs Ther. 1988 Mar;1(6):625-56. doi: 10.1007/BF02125750. Cardiovasc Drugs Ther. 1988. PMID: 3154329 Review.
-
Co-dergocrine mesylate inhibits the increase in plasma catecholamines caused by nifedipine in essential hypertension.Eur J Clin Pharmacol. 1990;39(5):435-9. doi: 10.1007/BF00280932. Eur J Clin Pharmacol. 1990. PMID: 2076734 Clinical Trial.
-
Nifedipine-prazosin interaction in patients with essential hypertension.Cardiovasc Drugs Ther. 1989 Jun;3(3):413-5. doi: 10.1007/BF01858112. Cardiovasc Drugs Ther. 1989. PMID: 2487537 Clinical Trial.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical